Price movement over the last 24 hours
Agilent Technologies Inc vs Msci Inc — how do they compare? Agilent Technologies Inc trades at $128.2 (market cap $37.04B), while Msci Inc trades at $598.6 (market cap $44.27B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays the higher dividend (1.35%). Which is the better fit depends on your goals.
| A | MSCI | |
|---|---|---|
Market Cap | $37.04B | $44.27B |
Sector | Health | Financials |
52-Week High | $157.20 | $643.83 |
52-Week Low | $110.24 | $511.84 |
Enterprise Value | $38.59B | $50.43B |
Dividend Yield | 0.78% | 1.35% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
MSCI trades at $608.09, up 0.83% with a bullish technical outlook and strong fundamental performance. The company delivered three consecutive quarterly earnings beats, maintains exceptional profit margins above 40%, and shows consistent revenue growth. Recent strategic acquisitions and AI integration initiatives position MSCI for continued market leadership in financial analytics and index services.
With 69% analyst buy ratings and a $700.50 consensus price target representing 15% upside, MSCI offers growth potential despite premium valuations. Key risks include high debt levels and market classification decisions impacting revenue streams. The stock's current technical setup near pivot point $606 suggests potential for continued upward momentum if earnings momentum persists.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →